Shenzhen Weizhijun Biotechnology

Shenzhen Weizhijun Biotechnology is a clinical-stage biopharmaceutical company based in Shenzhen, China, focused on the discovery and development of innovative small molecule therapeutics for oncology and autoimmune diseases. The company utilizes a proprietary structure-based drug design (SBDD) platform to develop highly selective inhibitors against challenging biological targets. Its lead candidate, WZJ-101, is a potent and selective CDK2 inhibitor currently in Phase 1 clinical trials for the treatment of advanced solid tumors. Weizhijun's pipeline also includes programs targeting other cell cycle regulators and kinases, aiming to address unmet medical needs and overcome drug resistance in cancer therapy. The company was founded in 2021 by a team of experienced drug discovery scientists and has secured significant venture capital funding to advance its clinical programs.